德国拜耳利伐沙班的价格贵不贵

Rivaroxaban is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson. On September 15 and October 1, 2008, Rivaroxaban was approved for marketing in Canada and the European Union respectively. In March 2009, Rivaroxaban was approved by the State Food and Drug Administration for marketing. Rivaroxaban was approved by the FDA on July 1, 2011. The drug is used to prevent deep vein thrombosis in patients undergoing knee or hip replacement surgery.

The recommended initial dose of Rivaroxaban for the treatment of acute venous thrombosis (DVT) is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of recurrent PE from DVT. Patients should note: Rivaroxaban 10 mg can be taken with food or alone. Rivaroxaban 15 mg or 20 mg tablets should be taken with food. While patients are receiving Rivaroxaban treatment, they are not allowed to increase or decrease the drug dosage without authorization. Increasing the dosage of Rivaroxaban will not make the condition improve quickly, but will lead to side effects. Only correct medication will help the condition, so patients should strictly follow the doctor's instructions.

Bayer is headquartered in Leverkusen, Germany. Polymers, pharmaceuticals and health care, chemicals and agriculture are the company's four pillar industries. The company's product categories exceed 10,000 types. The company has produced aspirin, heroin, Rivaroxaban and other products.

Is the price of Bayer's Rivaroxaban expensive in Germany?

It is understood that the current cost-effective specifications of Rivaroxaban are: 20mg*28 tablets and 15mg*28 tablets, which sell for about $350. Affected by factors such as exchange rate fluctuations, prices are not fixed. If patients want to know the specific price information of rivaroxaban, they can consult the medical companion travel service.

Recommended related hot articles: /newsDetail/89982.html